GlassScriptPhysician profile
Andrew J Bernstein
NPI 1346458833
$2,090.92
in general payments reported to CMS, 2019-2025
34 companies · $376 in 2025
The $376 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $266 · 2021: $202 · 2022: $260 · 2023: $240 · 2024: $464 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,045 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,045.08 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $476.18 | 2021-2025 | Prolaris |
| Astellas Pharma US INC | $193.82 | 2019-2021 | |
| Tolmar, INC. | $190.15 | 2024-2025 | Eligard |
| Antares Pharma, INC. | $177.03 | 2019-2025 | Xyosted |
| Boston Scientific Corporation | $95.84 | 2022 | |
| Dendreon Pharmaceuticals LLC | $88.65 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.14 | 2019-2021 | |
| Pfizer INC. | $61.57 | 2020-2025 | |
| Axonics, INC. | $56.03 | 2020-2023 | Axonics, Bulkamid |
| Endo Pharmaceuticals INC. | $55.10 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $52.76 | 2024-2025 | Imfinzi, Lynparza |
| Olympus America INC. | $48.95 | 2025 | Itind System |
| Progenics Pharmaceuticals, INC. | $40.92 | 2025 | |
| Medtronic USA, INC. | $38.34 | 2020 | |
| Urogen Pharma, INC. | $36.20 | 2024-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $36.11 | 2024-2025 | |
| Verity Pharmaceuticals INC. | $35.20 | 2025 | Trelstar |
| Sumitomo Pharma America, INC. | $34.50 | 2024-2025 | Gemtesa |
| Teleflex LLC | $31.98 | 2021-2022 | |
| Myovant Sciences INC. | $28.35 | 2022 | |
| Merck Sharp & Dohme LLC | $27.70 | 2019-2022 | |
| Urovant Sciences INC | $26.49 | 2022 | |
| Metuchen Pharmaceuticals | $22.89 | 2020-2021 | |
| Endo USA, INC. | $18.89 | 2025 | Aveed, Xiaflex |
| Halozyme INC | $16.53 | 2023 | |
| Clarus Therapeutics INC. | $16.23 | 2021 | |
| Arteriocyte Medical Systems, INC. | $16.02 | 2020 | |
| Mindray Ds USA, INC. | $15.42 | 2022 | |
| Acerus Pharmaceuticals Corporation | $14.53 | 2020 | |
| Medtronic, INC. | $13.60 | 2022 | |
| Mission Pharmacal Company | $13.56 | 2023 | |
| Eisai INC. | $13.24 | 2019 | |
| 180 Medical, INC. | $12.54 | 2021 | |
| Allergan, INC. | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Bernstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.